Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Agios Pharmaceuticals, Inc. (AGIO)
USD40.55
-0.68 (-1.65%)
US NASDAQ Healthcare Biotechnology
Address
88 Sidney Street 02139-4169
Cambridge, MA, US
Cambridge, MA, US
CEO
Brian Goff
Website
agios.com
IPO
2013-07-24
CIK 1439222 ISIN US00847X1046
Also trades on
London Stock Exchange · 0HB0.L (USD)
NASDAQ Global Select · AGIO (USD)
Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
News Sentiment (7d)
6 articles
- Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone Investors Business Daily
- Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) The Motley Fool
- Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? Zacks Investment Research
- U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD40.55
-0.68 (-1.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.59
Float Shares
54.41M
Free Float %
91.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.72% | +2.90% | -14.98% | -0.29% | -35.85% | +2.83% | -3.95% | +10.24% | -48.47% | -37.59% | -10.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (29 ratings, all time)
Buy
Price Targets & DCF
Current price
40.55
Low
25.00
-38.3%
Consensus
37.75
-6.9%
Median
38.00
-6.3%
High
50.00
+23.3%
Ratings Trend (MoM)
70% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
43.00
+6.0%
|
| Last Quarter | 3 |
41.67
+2.8%
|
| Last Year | 10 |
41.20
+1.6%
|
| All Time | 21 |
46.43
+14.5%
|
Quality scores
Altman Z-Score
11.81
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+48.0% ★ Q1'26: +137.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-161.2% Q1'26: -9.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-931.6% Q1'26: -576.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-873.9% Q1'26: -530.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-117.8% Q1'26: -107.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: +2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q1'26: -0.08× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
65.36M
est: 201.66M (-67.6%)
|
59.12M
est: 81.61M (-27.6%)
|
69.89M
est: 58.11M (+20.3%)
|
43.01M
est: 46.60M (-7.7%)
|
94.39M
est: 82.13M (+14.9%)
|
117.91M
est: 116.13M (+1.5%)
|
—
est: 199.05M (-100.0%)
|
—
est: 558.8K (-100.0%)
|
14.24M
est: 13.91M (+2.4%)
|
26.82M
est: 31.31M (-14.3%)
|
36.50M
est: 35.15M (+3.8%)
|
54.03M
est: 46.12M (+17.1%)
|
120.21M
100.74M – 150.56M
+160.6% YoY
|
259.97M
174.57M – 352.69M
+116.3% YoY
|
406.18M
406.18M – 406.18M
+56.2% YoY
|
530.90M
339.64M – 716.01M
+30.7% YoY
|
688.59M
440.51M – 928.67M
+29.7% YoY
|
| EBITDA |
-52.77M
est: -33.97M (-55.3%)
|
-115.36M
est: -98.58M (-17.0%)
|
-195.28M
est: -202.90M (+3.8%)
|
-314.36M
est: -303.02M (-3.7%)
|
-338.86M
est: -358.69M (+5.5%)
|
-394.85M
est: -407.35M (+3.1%)
|
-310.53M
est: -313.04M (+0.8%)
|
-337.73M
est: -1.98B (+83.0%)
|
-380.48M
est: -292.75M (-30.0%)
|
-384.86M
est: -18.78M (-1,948.9%)
|
-420.08M
est: -21.09M (-1,891.7%)
|
-466.96M
est: -27.67M (-1,587.3%)
|
-72.12M
-90.34M – -60.44M
-160.6% YoY
|
-155.98M
-211.61M – -104.74M
-116.3% YoY
|
-243.71M
-243.71M – -243.71M
-56.2% YoY
|
-318.54M
-429.61M – -203.78M
-30.7% YoY
|
-413.15M
-557.20M – -264.31M
-29.7% YoY
|
| EBIT |
-54.13M
est: -35.64M (-51.9%)
|
-118.70M
est: -102.67M (-15.6%)
|
-200.99M
est: -211.76M (+5.1%)
|
-320.79M
est: -315.43M (-1.7%)
|
-346.03M
est: -384.00M (+9.9%)
|
-411.47M
est: -430.64M (+4.5%)
|
-329.31M
est: -332.09M (+0.8%)
|
-356.51M
est: -2.13B (+83.3%)
|
-389.05M
est: -426.86M (+8.9%)
|
-391.49M
est: -18.78M (-1,984.2%)
|
-425.74M
est: -21.09M (-1,918.5%)
|
-472.13M
est: -27.67M (-1,606.0%)
|
-72.12M
-90.34M – -60.44M
-160.6% YoY
|
-155.98M
-211.61M – -104.74M
-116.3% YoY
|
-243.71M
-243.71M – -243.71M
-56.2% YoY
|
-318.54M
-429.61M – -203.78M
-30.7% YoY
|
-413.15M
-557.20M – -264.31M
-29.7% YoY
|
| Net Income |
-53.50M
est: -34.56M (-54.8%)
|
-117.73M
est: -101.66M (-15.8%)
|
-198.47M
est: -209.07M (+5.1%)
|
-314.67M
est: -309.40M (-1.7%)
|
-346.03M
est: -366.36M (+5.5%)
|
-411.47M
est: -415.55M (+1.0%)
|
-327.37M
est: -341.28M (+4.1%)
|
1.60B
est: 37.63B (-95.7%)
|
-231.80M
est: -299.44M (+22.6%)
|
-352.09M
est: -364.93M (+3.5%)
|
673.73M
est: 650.08M (+3.6%)
|
-412.78M
est: -409.42M (-0.8%)
|
-360.23M
-427.11M – -315.74M
+12.0% YoY
|
-287.33M
-358.43M – -211.57M
+20.2% YoY
|
-198.44M
-278.85M – -81.16M
+30.9% YoY
|
-106.55M
-154.85M – -56.65M
+46.3% YoY
|
22.73M
12.08M – 33.03M
+121.3% YoY
|
| SGA |
19.12M
est: 20.49M (-6.7%)
|
35.99M
est: 35.68M (+0.9%)
|
50.71M
est: 54.85M (-7.5%)
|
71.12M
est: 179.98M (-60.5%)
|
114.15M
est: 317.19M (-64.0%)
|
132.03M
est: 448.50M (-70.6%)
|
106.12M
est: 165.55M (-35.9%)
|
121.45M
est: 2.16M (+5,527.2%)
|
121.67M
est: 53.73M (+126.5%)
|
119.90M
est: 135.54M (-11.5%)
|
156.78M
est: 152.19M (+3.0%)
|
180.28M
est: 199.69M (-9.7%)
|
520.42M
436.13M – 651.83M
+160.6% YoY
|
1.13B
755.79M – 1.53B
+116.3% YoY
|
1.76B
1.76B – 1.76B
+56.2% YoY
|
2.30B
1.47B – 3.10B
+30.7% YoY
|
2.98B
1.91B – 4.02B
+29.7% YoY
|
| EPS |
-1.59
est: -2.04 (+21.9%)
|
-3.15
est: -2.60 (-21.1%)
|
-5.07
est: -5.24 (+3.3%)
|
-6.75
est: -6.42 (-5.1%)
|
-6.03
est: -6.14 (+1.8%)
|
-6.61
est: -6.98 (+5.3%)
|
-4.74
est: -4.67 (-1.4%)
|
-6.36
est: 25.51 (-124.9%)
|
-4.23
est: -6.29 (+32.8%)
|
-6.33
est: -6.49 (+2.5%)
|
11.86
est: 11.44 (+3.7%)
|
-7.12
est: -7.06 (-0.8%)
|
-6.13
-7.37 – -5.45
+13.2% YoY
|
-4.68
-6.18 – -3.65
+23.7% YoY
|
-3.22
-4.81 – -1.40
+31.2% YoY
|
-1.84
-2.67 – -0.98
+42.9% YoY
|
0.39
0.21 – 0.57
+121.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-30 | Truist Securities | Buy | Buy | Maintain |
| 2026-04-21 | B of A Securities | Buy | Buy | Maintain |
| 2026-04-20 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-314.81M
OE per share TTM
-5.40
Owner's Yield
-19.13%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
241.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
31
Total invested
13.44M
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Andrew J. M. Spokes | 3.96M | 7.10% | — | 3.96M | — | — | IN | United Kingdom | 2023-11-09 | ↗ |
| 2 | Daniel S. Short | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 3 | David T. Kim | 3.96M | 7.10% | — | 3.96M | — | — | IN | Delaware | 2023-11-09 | ↗ |
| 4 | Edric C. Saito | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 5 | Hannah E. Dunn | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 6 | John R. Warren | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 7 | Joshua J. Dapice | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 8 | Mark C. Wehrly | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 9 | Michael G. Linn | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 10 | Nicolas Giauque | 3.96M | 7.10% | — | 3.96M | — | — | IN | France | 2023-11-09 | ↗ |
| 11 | Philip D. Dreyfuss | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 12 | Rajiv A. Patel | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 13 | Richard B. Fried | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 14 | Thomas G. Roberts, Jr. | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 15 | Varun N. Gehani | 3.96M | 7.10% | — | 3.96M | — | — | IN | Delaware | 2023-11-09 | ↗ |
| 16 | William Seybold | 3.96M | 7.10% | — | 3.96M | — | — | IN | United States | 2023-11-09 | ↗ |
| 17 | Farallon Partners, L.L.C. | 3.79M | 6.80% | — | 3.79M | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 18 | Farallon Healthcare Partners (GP), L.L.C. | 2.01M | 3.60% | — | 2.01M | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 19 | Farallon Healthcare Partners Master, L.P. | 2.01M | 3.60% | — | 2.01M | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 20 | Farallon Capital Offshore Investors II, L.P. | 700.3K | 1.30% | — | 700.3K | — | — | PN | Cayman Islands | 2023-11-09 | ↗ |
| 21 | Farallon Capital Institutional Partners, L.P. | 428.3K | 0.80% | — | 428.3K | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 22 | Farallon Capital Partners, L.P. | 332.4K | 0.60% | — | 332.4K | — | — | PN | California | 2023-11-09 | ↗ |
| 23 | Farallon Capital F5 Master I, L.P. | 172.1K | 0.30% | — | 172.1K | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 24 | Farallon F5 (GP), L.L.C. | 172.1K | 0.30% | — | 172.1K | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 25 | Farallon Capital Institutional Partners II, L.P. | 125.0K | 0.20% | — | 125.0K | — | — | PN | California | 2023-11-09 | ↗ |
| 26 | Farallon Institutional (GP) V, L.L.C. | 85.5K | 0.20% | — | 85.5K | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 27 | Four Crossings Institutional Partners V, L.P. | 85.5K | 0.20% | — | 85.5K | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 28 | Farallon Capital (AM) Investors, L.P. | 52.8K | 0.10% | — | 52.8K | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 29 | Farallon Capital Institutional Partners III, L.P. | 50.8K | 0.10% | — | 50.8K | — | — | PN | Delaware | 2023-11-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
31
-225 vs prev Q
New positions
5
Closed positions
212
Increased
12
Reduced
12
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.70M +1.7M (+100.0%) | 46.31B +46.3B (+100.0%) | 2.93% +2.935 pp | 0.07% +0.070 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 5.59M -10.5K (-0.2%) | 152.28M -72.7M (-32.3%) | 9.65% -0.025 pp | 0.00% -0.001 pp | USD54.10 -49.7% | 50 qtrs — |
| 3 | BLACKROCK, INC. | 5.24M +689.7K (+15.2%) | 142.51M -40.0M (-21.9%) | 9.03% +1.184 pp | 0.00% -0.001 pp | USD41.93 -35.1% | 6 qtrs — |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 5.16M -621.6K (-10.8%) | 140.44M -91.6M (-39.5%) | 8.90% -1.079 pp | 0.66% -0.287 pp | USD30.35 -10.3% | 25 qtrs — |
| 5 | STATE STREET CORP | 3.11M +845.4K (+37.4%) | 84.60M -6.2M (-6.9%) | 5.36% +1.456 pp | 0.00% 0.000 pp | USD34.92 -22.1% | 50 qtrs — |
| 6 | ARMISTICE CAPITAL, LLC | 3.04M +2.3M (+297.4%) | 82.64M +52.0M (+169.5%) | 5.24% +3.918 pp | 0.98% +0.528 pp | USD27.41 -0.7% | 14 qtrs — |
| 7 | ERSTE ASSET MANAGEMENT GMBH | 2.80M +40.0K (+1.4%) | 76.34M -32.2M (-29.7%) | 4.82% +0.052 pp | 0.64% -0.408 pp | USD35.98 -24.3% | 29 qtrs — |
| 8 | D. E. SHAW & CO., INC. | 1.84M +1.5M (+399.6%) | 50.01M +35.2M (+238.8%) | 3.17% +2.534 pp | 0.03% +0.019 pp | USD28.57 -4.7% | 33 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.41M -2.8K (-0.2%) | 38.48M -18.4M (-32.3%) | 2.44% -0.007 pp | 0.00% -0.001 pp | USD46.15 -41.0% | 50 qtrs — |
| 10 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.36M +373.4K (+37.8%) | 37.04M -2.6M (-6.5%) | 2.35% +0.643 pp | 0.04% -0.060 pp | USD36.21 -24.8% | 38 qtrs — |
| 11 | CITADEL ADVISORS LLC | 1.35M +857.0K (+174.2%) | 36.72M +17.0M (+85.9%) | 2.33% +1.478 pp | 0.01% +0.003 pp | USD29.28 -7.0% | 38 qtrs — |
| 12 | BIOIMPACT CAPITAL LLC | 1.30M +1.3M (+100.0%) | 35.48M +35.5M (+100.0%) | 2.25% +2.248 pp | 4.06% +4.060 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 13 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 1.28M +— (+0.0%) | 34.83M -16.5M (-32.2%) | 2.21% -0.002 pp | 0.94% -0.604 pp | USD33.59 -19.0% | 10 qtrs — |
| 14 | GW&K INVESTMENT MANAGEMENT, LLC | 1.21M +354.4K (+41.5%) | 32.86M -1.4M (-4.0%) | 2.08% +0.604 pp | 0.28% -0.019 pp | USD29.23 -6.9% | 8 qtrs — |
| 15 | TCG CROSSOVER MANAGEMENT, LLC | 1.18M -248.2K (-17.4%) | 32.17M -25.2M (-44.0%) | 2.04% -0.430 pp | 1.06% -1.759 pp | USD36.79 -26.0% | 3 qtrs — |
| 16 | JANE STREET GROUP, LLC | 1.12M +725.9K (+183.7%) | 30.51M +14.7M (+92.4%) | 1.93% +1.246 pp | 0.00% +0.002 pp | USD31.53 -13.7% | 31 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 1.03M +229.2K (+28.5%) | 28.14M -4.2M (-12.9%) | 1.78% +0.389 pp | 0.00% -0.001 pp | USD41.09 -33.8% | 49 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 1.00M -16.9K (-1.7%) | 27.34M -13.6M (-33.3%) | 1.73% -0.030 pp | 0.01% -0.003 pp | USD31.04 -12.3% | 32 qtrs — |
| 19 | MORGAN STANLEY | 894.0K +477.0K (+114.4%) | 24.34M +7.6M (+45.4%) | 1.54% +0.822 pp | 0.00% +0.000 pp | USD29.74 -8.5% | 50 qtrs — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 836.0K +568.7K (+212.8%) | 22.76M +12.0M (+112.1%) | 1.44% +0.981 pp | 0.00% +0.001 pp | USD30.38 -10.4% | 47 qtrs — |
| 21 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 799.2K -159.4K (-16.6%) | 21.75M -16.7M (-43.5%) | 1.38% -0.276 pp | 1.12% -1.133 pp | USD35.37 -23.0% | 28 qtrs — |
| 22 | CAPITAL INTERNATIONAL INVESTORS | 703.9K +703.9K (+100.0%) | 19.16M +19.2M (+100.0%) | 1.21% +1.211 pp | 0.00% +0.003 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 637.9K -1.0M (-61.5%) | 17.36M -49.1M (-73.9%) | 1.10% -1.760 pp | 0.00% -0.005 pp | USD47.71 -42.9% | 47 qtrs — |
| 24 | BALYASNY ASSET MANAGEMENT L.P. | 635.1K +139.6K (+28.2%) | 17.29M -2.6M (-13.1%) | 1.10% +0.240 pp | 0.02% -0.003 pp | USD37.30 -27.0% | 2 qtrs — |
| 25 | SCS CAPITAL MANAGEMENT LLC | 598.8K +— (+0.0%) | 16.30M -7.7M (-32.2%) | 1.03% -0.004 pp | 0.17% -0.089 pp | USD29.30 -7.1% | 4 qtrs — |
| 26 | WELLINGTON MANAGEMENT GROUP LLP | 597.8K -1.9M (-75.8%) | 16.27M -82.9M (-83.6%) | 1.03% -3.235 pp | 0.00% -0.015 pp | USD39.26 -30.7% | 50 qtrs — |
| 27 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 562.6K +32.5K (+6.1%) | 15.32M -6.0M (-28.0%) | 0.97% +0.053 pp | 0.04% -0.027 pp | USD31.71 -14.2% | 20 qtrs — |
| 28 | BANK OF AMERICA CORP /DE/ | 539.3K -590.7K (-52.3%) | 14.68M -30.7M (-67.6%) | 0.93% -1.020 pp | 0.00% -0.002 pp | USD29.74 -8.5% | 49 qtrs — |
| 29 | FORESITE CAPITAL MANAGEMENT VI LLC | 530.0K +530.0K (+100.0%) | 14.43M +14.4M (+100.0%) | 0.91% +0.914 pp | 4.36% +4.361 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 30 | NORTHERN TRUST CORP | 511.9K -43.5K (-7.8%) | 13.93M -8.4M (-37.5%) | 0.88% -0.076 pp | 0.00% -0.001 pp | USD45.94 -40.7% | 50 qtrs — |
| 31 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 504.5K +101.5K (+25.2%) | 13.73M -2.4M (-15.1%) | 0.87% +0.175 pp | 0.02% -0.002 pp | USD38.41 -29.1% | 7 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 482.6K +436.0 (+0.1%) | 13.14M -6.2M (-32.1%) | 0.83% +0.000 pp | 0.00% -0.001 pp | USD51.01 -46.6% | 50 qtrs — |
| 33 | ARROWMARK COLORADO HOLDINGS LLC | 466.2K -213.8K (-31.4%) | 12.69M -14.6M (-53.5%) | 0.80% -0.370 pp | 0.28% -0.228 pp | USD49.02 -44.5% | 41 qtrs — |
| 34 | ALGERT GLOBAL LLC | 414.2K +378.4K (+1,058.0%) | 11.28M +9.8M (+685.2%) | 0.71% +0.653 pp | 0.18% +0.152 pp | USD27.45 -0.8% | 8 qtrs — |
| 35 | MILLENNIUM MANAGEMENT LLC | 398.3K +393.2K (+7,788.0%) | 10.84M +10.6M (+5,249.1%) | 0.69% +0.678 pp | 0.00% +0.005 pp | USD27.29 -0.3% | 30 qtrs — |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | 378.4K +378.4K (+100.0%) | 10.30M +10.3M (+100.0%) | 0.65% +0.653 pp | 0.01% +0.011 pp | USD27.22 +0.0% | 9 qtrs — |
| 37 | MARSHALL WACE, LLP | 353.6K +126.8K (+55.9%) | 9.63M +521.3K (+5.7%) | 0.61% +0.219 pp | 0.01% -0.001 pp | USD34.53 -21.2% | 10 qtrs — |
| 38 | LEGAL & GENERAL GROUP PLC | 328.2K +5.3K (+1.6%) | 8.93M -4.0M (-31.1%) | 0.56% +0.007 pp | 0.00% -0.001 pp | USD40.83 -33.3% | 46 qtrs — |
| 39 | VESTAL POINT CAPITAL, LP | 325.0K +198.0K (+155.9%) | 8.85M +3.7M (+73.5%) | 0.56% +0.341 pp | 0.30% +0.071 pp | USD32.27 -15.6% | 2 qtrs — |
| 40 | BARCLAYS PLC | 320.4K +139.9K (+77.6%) | 8.72M +704.1K (+8.8%) | 0.55% +0.241 pp | 0.00% +0.000 pp | USD32.18 -15.4% | 50 qtrs — |
| 41 | TWO SIGMA INVESTMENTS, LP | 300.2K +240.5K (+403.4%) | 8.17M +5.8M (+241.4%) | 0.52% +0.415 pp | 0.01% +0.008 pp | USD29.79 -8.6% | 2 qtrs — |
| 42 | NUVEEN, LLC | 297.9K +178.3K (+149.1%) | 8.11M +3.3M (+68.9%) | 0.51% +0.308 pp | 0.00% +0.001 pp | USD28.54 -4.6% | 4 qtrs — |
| 43 | JPMORGAN CHASE & CO | 251.8K +68.7K (+37.5%) | 6.85M -496.3K (-6.8%) | 0.43% +0.117 pp | 0.00% +0.000 pp | USD34.28 -20.6% | 50 qtrs — |
| 44 | BNP PARIBAS ARBITRAGE, SNC | 242.7K +228.0K (+1,551.0%) | 6.61M +6.0M (+1,019.6%) | 0.42% +0.393 pp | 0.00% +0.003 pp | USD27.55 -1.2% | 49 qtrs — |
| 45 | TREXQUANT INVESTMENT LP | 226.6K +226.6K (+100.0%) | 6.17M +6.2M (+100.0%) | 0.39% +0.391 pp | 0.06% +0.055 pp | USD27.22 +0.0% | 9 qtrs — |
| 46 | PALO ALTO INVESTORS LP | 212.5K -53.0K (-20.0%) | 5.78M -4.9M (-45.7%) | 0.37% -0.092 pp | 0.81% -1.167 pp | USD29.30 -7.1% | 4 qtrs — |
| 47 | PICTET ASSET MANAGEMENT HOLDING SA | 205.0K -67.1K (-24.7%) | 5.57M -5.1M (-47.9%) | 0.35% -0.117 pp | 0.01% -0.005 pp | USD24.78 +9.8% | 10 qtrs — |
| 48 | POINT72 ASSET MANAGEMENT, L.P. | 200.0K +193.5K (+2,973.6%) | 5.44M +5.2M (+1,984.3%) | 0.35% +0.334 pp | 0.01% +0.006 pp | USD27.64 -1.5% | 2 qtrs — |
| 49 | BANK OF NEW YORK MELLON CORP | 196.9K -73.2K (-27.1%) | 5.36M -5.5M (-50.6%) | 0.34% -0.128 pp | 0.00% -0.001 pp | USD42.22 -35.5% | 50 qtrs — |
| 50 | ADAR1 CAPITAL MANAGEMENT, LLC | 188.0K +151.0K (+408.1%) | 5.12M +3.6M (+244.6%) | 0.32% +0.260 pp | 0.38% +0.236 pp | USD27.86 -2.3% | 6 qtrs — |
| 51 | EDGESTREAM PARTNERS, L.P. | 168.0K +168.0K (+100.0%) | 4.57M +4.6M (+100.0%) | 0.29% +0.290 pp | 0.13% +0.129 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 52 | GROUP ONE TRADING, L.P. | 166.6K +166.6K (+100.0%) | 4.54M +4.5M (+100.0%) | 0.29% +0.287 pp | 0.01% +0.008 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 53 | TFG ASSET MANAGEMENT GP LTD | 162.0K +162.0K (+100.0%) | 4.41M +4.4M (+100.0%) | 0.28% +0.280 pp | 0.93% +0.930 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 54 | AMERICAN CENTURY COMPANIES INC | 151.5K +6.4K (+4.4%) | 4.12M -1.7M (-29.2%) | 0.26% +0.011 pp | 0.00% -0.001 pp | USD32.38 -15.9% | 14 qtrs — |
| 55 | MOORE CAPITAL MANAGEMENT, LP | 150.0K +95.0K (+172.7%) | 4.08M +1.9M (+84.9%) | 0.26% +0.164 pp | 0.06% +0.028 pp | USD32.33 -15.8% | 7 qtrs — |
| 56 | ALLIANZ ASSET MANAGEMENT GMBH | 148.0K +1.3K (+0.9%) | 4.03M -1.9M (-31.6%) | 0.25% +0.001 pp | 0.00% -0.003 pp | USD33.96 -19.8% | 43 qtrs — |
| 57 | HIGHVISTA STRATEGIES LLC | 147.7K -47.6K (-24.4%) | 4.02M -3.8M (-48.7%) | 0.25% -0.082 pp | 1.04% -0.887 pp | USD36.78 -26.0% | 4 qtrs — |
| 58 | HRT FINANCIAL LP | 146.5K +146.5K (+100.0%) | 3.99M +4.0M (+100.0%) | 0.25% +0.253 pp | 0.01% +0.013 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 59 | INVESCO LTD. | 142.6K +15.6K (+12.3%) | 3.88M -1.2M (-23.9%) | 0.25% +0.027 pp | 0.00% 0.000 pp | USD33.04 -17.6% | 45 qtrs — |
| 60 | IKARIAN CAPITAL, LLC | 137.2K -12.8K (-8.5%) | 3.73M -2.3M (-38.0%) | 0.24% -0.022 pp | 0.29% -0.316 pp | USD40.14 -32.2% | 2 qtrs — |
| 61 | EXOME ASSET MANAGEMENT LLC | 136.9K +136.9K (+100.0%) | 3.73M +3.7M (+100.0%) | 0.24% +0.236 pp | 1.78% +1.782 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 62 | UBS GROUP AG | 126.7K -116.1K (-47.8%) | 3.45M -6.3M (-64.6%) | 0.22% -0.201 pp | 0.00% -0.001 pp | USD37.08 -26.6% | 45 qtrs — |
| 63 | DEUTSCHE BANK AG\ | 122.9K -803.9K (-86.7%) | 3.34M -33.9M (-91.0%) | 0.21% -1.388 pp | 0.00% -0.011 pp | USD44.69 -39.1% | 50 qtrs — |
| 64 | SQUAREPOINT OPS LLC | 121.8K +121.8K (+100.0%) | 3.31M +3.3M (+100.0%) | 0.21% +0.210 pp | 0.00% +0.004 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 65 | JACOBS LEVY EQUITY MANAGEMENT, INC | 111.2K +111.2K (+100.0%) | 3.03M +3.0M (+100.0%) | 0.19% +0.192 pp | 0.01% +0.012 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 66 | ASSENAGON ASSET MANAGEMENT S.A. | 110.4K +43.3K (+64.5%) | 3.01M +310.7K (+11.5%) | 0.19% +0.074 pp | 0.00% +0.001 pp | USD35.08 -22.4% | 2 qtrs — |
| 67 | SWISS NATIONAL BANK | 108.9K +2.2K (+2.1%) | 2.96M -1.3M (-30.8%) | 0.19% +0.003 pp | 0.00% -0.001 pp | USD50.45 -46.0% | 49 qtrs — |
| 68 | RAFFERTY ASSET MANAGEMENT, LLC | 107.5K +39.3K (+57.6%) | 2.93M +187.5K (+6.8%) | 0.19% +0.068 pp | 0.01% +0.001 pp | USD31.77 -14.3% | 28 qtrs — |
| 69 | CAPTION MANAGEMENT, LLC | 107.3K -279.3K (-72.2%) | 2.92M -12.6M (-81.2%) | 0.19% -0.482 pp | 0.02% -0.101 pp | USD40.17 -32.2% | 26 qtrs — |
| 70 | UBS ASSET MANAGEMENT AMERICAS INC | 107.0K +121.0 (+0.1%) | 2.91M -1.4M (-32.1%) | 0.18% +0.000 pp | 0.00% 0.000 pp | USD34.66 -21.5% | 46 qtrs — |
| 71 | HUDSON BAY CAPITAL MANAGEMENT LP | 100.0K -22.5K (-18.4%) | 2.72M -2.2M (-44.6%) | 0.17% -0.039 pp | 0.01% -0.007 pp | USD29.64 -8.2% | 28 qtrs — |
| 72 | PARKMAN HEALTHCARE PARTNERS LLC | 99.6K -776.0 (-0.8%) | 2.71M -1.3M (-32.7%) | 0.17% -0.002 pp | 0.26% -0.162 pp | USD40.14 -32.2% | 2 qtrs — |
| 73 | CALIGAN PARTNERS LP | 90.0K +90.0K (+100.0%) | 2.45M +2.4M (+100.0%) | 0.16% +0.155 pp | 0.20% +0.202 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 74 | CITIGROUP INC | 88.2K +44.6K (+102.3%) | 2.40M +650.9K (+37.2%) | 0.15% +0.077 pp | 0.00% +0.000 pp | USD30.99 -12.2% | 50 qtrs — |
| 75 | TWO SIGMA ADVISERS, LP | 85.2K +71.6K (+526.5%) | 2.32M +1.8M (+324.8%) | 0.15% +0.124 pp | 0.00% +0.003 pp | USD29.28 -7.0% | 2 qtrs — |
| 76 | PRUDENTIAL FINANCIAL INC | 81.1K -17.2K (-17.5%) | 2.21M -1.7M (-44.0%) | 0.14% -0.030 pp | 0.00% -0.002 pp | USD30.11 -9.6% | 11 qtrs — |
| 77 | PANAGORA ASSET MANAGEMENT INC | 79.8K +79.8K (+100.0%) | 2.17M +2.2M (+100.0%) | 0.14% +0.138 pp | 0.01% +0.008 pp | USD27.22 +0.0% | 7 qtrs — |
| 78 | Y-INTERCEPT (HONG KONG) LTD | 79.8K +71.9K (+906.4%) | 2.17M +1.9M (+582.5%) | 0.14% +0.124 pp | 0.05% +0.041 pp | USD28.50 -4.5% | 2 qtrs — |
| 79 | LYNX1 CAPITAL MANAGEMENT LP | 79.6K +79.6K (+100.0%) | 2.17M +2.2M (+100.0%) | 0.14% +0.137 pp | 0.44% +0.439 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 80 | CENTIVA CAPITAL, LP | 79.5K +36.6K (+85.3%) | 2.16M +442.0K (+25.7%) | 0.14% +0.063 pp | 0.02% +0.001 pp | USD34.19 -20.4% | 2 qtrs — |
| 81 | FIRST TRUST ADVISORS LP | 78.7K +4.2K (+5.7%) | 2.14M -846.6K (-28.3%) | 0.14% +0.007 pp | 0.00% -0.001 pp | USD40.95 -33.5% | 43 qtrs — |
| 82 | WOODLINE PARTNERS LP | 74.4K +427.0 (+0.6%) | 2.03M -944.4K (-31.8%) | 0.13% +0.001 pp | 0.01% -0.006 pp | USD32.88 -17.2% | 4 qtrs — |
| 83 | RHUMBLINE ADVISERS | 74.2K -13.5K (-15.4%) | 2.02M -1.5M (-42.7%) | 0.13% -0.024 pp | 0.00% -0.001 pp | USD47.16 -42.3% | 47 qtrs — |
| 84 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 71.1K +71.1K (+100.0%) | 1.94M +1.9M (+100.0%) | 0.12% +0.123 pp | 0.02% +0.015 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 85 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 70.3K -25.8K (-26.8%) | 1.92M -1.9M (-50.3%) | 0.12% -0.045 pp | 0.00% -0.002 pp | USD37.96 -28.3% | 19 qtrs — |
| 86 | BOOTHBAY FUND MANAGEMENT, LLC | 67.2K +12.8K (+23.5%) | 1.83M -354.4K (-16.2%) | 0.12% +0.022 pp | 0.03% -0.005 pp | USD37.68 -27.8% | 2 qtrs — |
| 87 | KENNEDY CAPITAL MANAGEMENT LLC | 65.7K +41.0K (+166.4%) | 1.79M +798.0K (+80.7%) | 0.11% +0.071 pp | 0.04% +0.016 pp | USD28.94 -5.9% | 8 qtrs — |
| 88 | WELLS FARGO & COMPANY/MN | 64.8K +20.0K (+44.7%) | 1.76M -33.3K (-1.9%) | 0.11% +0.035 pp | 0.00% +0.000 pp | USD28.14 -3.3% | 50 qtrs — |
| 89 | ALLIANCEBERNSTEIN L.P. | 61.5K -9.0 (0.0%) | 1.67M -794.9K (-32.2%) | 0.11% 0.000 pp | 0.00% 0.000 pp | USD46.69 -41.7% | 50 qtrs — |
| 90 | TUDOR INVESTMENT CORP ET AL | 61.3K +61.3K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.11% +0.106 pp | 0.00% +0.003 pp | USD27.22 +0.0% | 1 qtrs NEW |
| 91 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 60.6K -10.7K (-15.0%) | 1.65M -1.2M (-42.3%) | 0.10% -0.019 pp | 0.00% -0.002 pp | USD31.76 -14.3% | 4 qtrs — |
| 92 | TD ASSET MANAGEMENT INC | 57.3K -71.0K (-55.3%) | 1.56M -3.6M (-69.7%) | 0.10% -0.123 pp | 0.00% -0.003 pp | USD36.45 -25.3% | 39 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.83
Neutral
Ratio by volume
3.00
Bullish
Buys
34
Sells
41
Shares acquired
695.8K
Shares disposed
159.0K
Cash buys
—
Cash sales
21.00
Net activity
+536,854
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Viswanadhan Krishnan | Officer | M-Exempt | D | Performance share units | 8,100 | 0.00 | — | 8,100 | D | ↗ |
| 2026-04-02 | Milanova Tsveta | Officer | S-Sale | D | Common stock | 3,262 | 34.71 | 113.2K | 46,829 | D | ↗ |
| 2026-04-02 | Jones Cecilia | Officer | S-Sale | D | Common stock | 3,141 | 34.71 | 109.0K | 54,998 | D | ↗ |
| 2026-04-02 | Goff Brian | Director / Officer | M-Exempt | D | Performance share units | 25,528 | 0.00 | — | 0 | D | ↗ |
| 2026-04-02 | Gheuens Sarah | Officer | M-Exempt | D | Performance share units | 8,500 | 0.00 | — | 8,500 | D | ↗ |
| 2026-04-02 | Burns James William | Officer | M-Exempt | A | Common stock | 8,500 | 0.00 | — | 52,586 | D | ↗ |
| 2026-03-05 | Viswanadhan Krishnan | Officer | S-Sale | D | Common stock | 2,959 | 27.80 | 82.3K | 5,141 | D | ↗ |
| 2026-03-03 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 5,272 | 28.88 | 152.3K | 868 | D | ↗ |
| 2026-03-02 | Washburn Theodore James Jr. | Officer | M-Exempt | D | Restricted stock units | 2,450 | 0.00 | — | 2,450 | D | ↗ |
| 2026-03-02 | Milanova Tsveta | Officer | M-Exempt | A | Common stock | 4,000 | 0.00 | — | 42,778 | D | ↗ |
| 2026-03-02 | Jones Cecilia | Officer | S-Sale | D | Common stock | 1,573 | 28.96 | 45.6K | 49,328 | D | ↗ |
| 2026-03-02 | Goff Brian | Director / Officer | M-Exempt | A | Common stock | 13,000 | 0.00 | — | 170,466 | D | ↗ |
| 2026-03-02 | Gheuens Sarah | Officer | M-Exempt | D | Restricted stock units | 5,666 | 0.00 | — | 5,667 | D | ↗ |
| 2026-03-02 | Burns James William | Officer | M-Exempt | A | Common stock | 4,000 | 0.00 | — | 35,718 | D | ↗ |
| 2026-03-01 | Washburn Theodore James Jr. | Officer | A-Award | A | Restricted stock units | 8,452 | 0.00 | — | 8,452 | D | ↗ |
| 2026-03-01 | Viswanadhan Krishnan | Officer | A-Award | A | Restricted stock units | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2026-03-01 | Milanova Tsveta | Officer | A-Award | A | Restricted stock units | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2026-03-01 | Jones Cecilia | Officer | A-Award | A | Restricted stock units | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2026-03-01 | Goff Brian | Director / Officer | A-Award | A | Stock options (right to buy) | 174,000 | 30.23 | 5.26M | 174,000 | D | ↗ |
| 2026-03-01 | Gheuens Sarah | Officer | A-Award | A | Restricted stock units | 22,000 | 0.00 | — | 22,000 | D | ↗ |
| 2026-03-01 | Burns James William | Officer | A-Award | A | Restricted stock units | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2026-01-05 | Milanova Tsveta | Officer | M-Exempt | D | Restricted stock units | 8,475 | 0.00 | — | 0 | D | ↗ |
| 2025-12-30 | Milanova Tsveta | Officer | M-Exempt | D | Performance share units | 6,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-30 | Jones Cecilia | Officer | M-Exempt | D | Performance share units | 6,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-30 | Goff Brian | Director / Officer | M-Exempt | D | Performance share units | 12,750 | 0.00 | — | 0 | D | ↗ |
| 2025-12-30 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 6,000 | 0.00 | — | 67,727 | D | ↗ |
| 2025-12-30 | Burns James William | Officer | M-Exempt | A | Common stock | 6,000 | 0.00 | — | 34,650 | D | ↗ |
| 2025-11-12 | Scadden David | Director | M-Exempt | A | Common stock | 200 | 18.09 | 3.6K | 17,803 | D | ↗ |
| 2025-11-11 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 2,454 | 25.01 | 61.4K | 64,181 | D | ↗ |
| 2025-10-30 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 200 | 25.01 | 5.0K | 61,927 | D | ↗ |
| 2025-10-27 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 3,302 | 43.92 | 145.0K | 61,727 | D | ↗ |
| 2025-10-08 | Scadden David | Director | M-Exempt | D | Stock options (right to buy) | 200 | 18.09 | 3.6K | 27,107 | D | ↗ |
| 2025-09-30 | Scadden David | Director | M-Exempt | D | Stock options (right to buy) | 200 | 18.09 | 3.6K | 27,307 | D | ↗ |
| 2025-09-26 | Jones Cecilia | Officer | S-Sale | D | Common stock | 3,651 | 36.77 | 134.2K | 33,870 | D | ↗ |
| 2025-09-05 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 8,546 | 36.87 | 315.1K | 868 | D | ↗ |
| 2025-08-27 | Scadden David | Director | M-Exempt | A | Common stock | 200 | 18.09 | 3.6K | 17,803 | D | ↗ |
| 2025-08-11 | Smith Cynthia | Director | M-Exempt | A | Common stock | 2,302 | 0.00 | — | 12,414 | D | ↗ |
| 2025-08-11 | Ballal Rahul D. | Director | M-Exempt | A | Common stock | 2,302 | 0.00 | — | 12,414 | D | ↗ |
| 2025-08-08 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 11,085 | 36.67 | 406.5K | 123,528 | D | ↗ |
| 2025-07-10 | Scadden David | Director | M-Exempt | A | Common stock | 1,400 | 18.09 | 25.3K | 19,003 | D | ↗ |
| 2025-07-09 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 11,914 | 25.01 | 298.0K | 73,185 | D | ↗ |
| 2025-07-08 | Backstrom Jay T. | Director | A-Award | A | Stock options (right to buy) | 23,393 | 36.28 | 848.7K | 23,393 | D | ↗ |
| 2025-07-01 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 8,374 | 0.00 | — | 65,362 | D | ↗ |
| 2025-06-24 | Milanova Tsveta | Officer | M-Exempt | D | Performance share units | 6,000 | 0.00 | — | 6,000 | D | ↗ |
| 2025-06-24 | Jones Cecilia | Officer | M-Exempt | D | Performance share units | 6,000 | 0.00 | — | 6,000 | D | ↗ |
| 2025-06-24 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 6,229 | 33.54 | 208.9K | 111,922 | D | ↗ |
| 2025-06-24 | Gheuens Sarah | Officer | M-Exempt | D | Performance share units | 6,000 | 0.00 | — | 6,000 | D | ↗ |
| 2025-06-24 | Burns James William | Officer | M-Exempt | D | Performance share units | 6,000 | 0.00 | — | 6,000 | D | ↗ |
| 2025-06-20 | Smith Cynthia | Director | M-Exempt | A | Common stock | 2,120 | 0.00 | — | 10,112 | D | ↗ |
| 2025-06-20 | Scadden David | Director | M-Exempt | A | Common stock | 2,120 | 0.00 | — | 17,603 | D | ↗ |
| 2025-06-20 | Owen Adams Catherine | Director | M-Exempt | D | Restricted stock units | 2,120 | 0.00 | — | 0 | D | ↗ |
| 2025-06-20 | Ho Maykin | Director | M-Exempt | A | Common stock | 2,120 | 0.00 | — | 17,032 | D | ↗ |
| 2025-06-20 | Foster-Cheek Kaye I | Director | M-Exempt | D | Restricted stock units | 2,120 | 0.00 | — | 0 | D | ↗ |
| 2025-06-20 | FOUSE JACQUALYN A | Director | M-Exempt | D | Restricted stock units | 2,120 | 0.00 | — | 0 | D | ↗ |
| 2025-06-20 | CAPELLO JEFFREY D | Director | M-Exempt | D | Restricted stock units | 2,120 | 0.00 | — | 0 | D | ↗ |
| 2025-06-20 | Ballal Rahul D. | Director | M-Exempt | D | Restricted stock units | 2,120 | 0.00 | — | 0 | D | ↗ |
| 2025-06-18 | Smith Cynthia | Director | A-Award | A | Stock options (right to buy) | 15,768 | 35.50 | 559.8K | 15,768 | D | ↗ |
| 2025-06-18 | Scadden David | Director | A-Award | A | Restricted stock units | 2,816 | 0.00 | — | 2,816 | D | ↗ |
| 2025-06-18 | Owen Adams Catherine | Director | A-Award | A | Restricted stock units | 2,816 | 0.00 | — | 2,816 | D | ↗ |
| 2025-06-18 | Ho Maykin | Director | A-Award | A | Stock options (right to buy) | 15,768 | 35.50 | 559.8K | 15,768 | D | ↗ |
| 2025-06-18 | Foster-Cheek Kaye I | Director | A-Award | A | Restricted stock units | 2,816 | 0.00 | — | 2,816 | D | ↗ |
| 2025-06-18 | FOUSE JACQUALYN A | Director | A-Award | A | Restricted stock units | 2,816 | 0.00 | — | 2,816 | D | ↗ |
| 2025-06-18 | CAPELLO JEFFREY D | Director | A-Award | A | Restricted stock units | 2,861 | 0.00 | — | 2,861 | D | ↗ |
| 2025-06-18 | Ballal Rahul D. | Director | A-Award | A | Restricted stock units | 2,816 | 0.00 | — | 2,816 | D | ↗ |
| 2025-06-13 | Owen Adams Catherine | Director | M-Exempt | A | Common stock | 1,977 | 0.00 | — | 3,953 | D | ↗ |
| 2025-06-13 | CAPELLO JEFFREY D | Director | M-Exempt | D | Restricted stock units | 1,977 | 0.00 | — | 1,976 | D | ↗ |
| 2025-04-10 | FOUSE JACQUALYN A | Director | S-Sale | D | Common stock | 7,497 | 25.90 | 194.2K | 149,220 | D | ↗ |
| 2025-04-08 | FOUSE JACQUALYN A | Director | M-Exempt | A | Common stock | 15,933 | 0.00 | — | 156,717 | D | ↗ |
| 2025-03-05 | Viswanadhan Krishnan | Officer | A-Award | A | Stock options (right to buy) | 55,374 | 33.95 | 1.88M | 55,374 | D | ↗ |
| 2025-03-03 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 697 | 35.54 | 24.8K | 7,691 | D | ↗ |
| 2025-03-03 | Milanova Tsveta | Officer | S-Sale | D | Common stock | 1,681 | 35.54 | 59.7K | 22,892 | D | ↗ |
| 2025-03-03 | Jones Cecilia | Officer | S-Sale | D | Common stock | 594 | 35.54 | 21.1K | 21,843 | D | ↗ |
| 2025-03-03 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 8,794 | 35.54 | 312.5K | 92,345 | D | ↗ |
| 2025-03-03 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 1,681 | 35.54 | 59.7K | 53,897 | D | ↗ |
| 2025-03-03 | Burns James William | Officer | S-Sale | D | Common stock | 1,187 | 35.54 | 42.2K | 21,463 | D | ↗ |
| 2025-03-01 | Washburn Theodore James Jr. | Officer | M-Exempt | D | Restricted stock units | 777 | 0.00 | — | 0 | D | ↗ |
| 2025-03-01 | Milanova Tsveta | Officer | M-Exempt | D | Restricted stock units | 5,667 | 0.00 | — | 11,333 | D | ↗ |
| 2025-03-01 | Jones Cecilia | Officer | M-Exempt | A | Common stock | 5,667 | 0.00 | — | 27,510 | D | ↗ |
| 2025-03-01 | Goff Brian | Director / Officer | M-Exempt | D | Restricted stock units | 18,000 | 0.00 | — | 36,000 | D | ↗ |
| 2025-03-01 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 3,833 | 0.00 | — | 48,235 | D | ↗ |
| 2025-03-01 | Burns James William | Officer | A-Award | A | Stock options (right to buy) | 43,500 | 35.54 | 1.55M | 43,500 | D | ↗ |
| 2025-02-05 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 2,272 | 34.39 | 78.1K | 5,437 | D | ↗ |
| 2025-02-01 | Washburn Theodore James Jr. | Officer | M-Exempt | D | Restricted stock units | 6,896 | 0.00 | — | 0 | D | ↗ |
| 2025-01-06 | Milanova Tsveta | Officer | S-Sale | D | Common stock | 2,804 | 32.18 | 90.2K | 18,906 | D | ↗ |
| 2025-01-03 | Milanova Tsveta | Officer | M-Exempt | A | Common stock | 8,476 | 0.00 | — | 21,710 | D | ↗ |
| 2024-12-11 | Scadden David | Director | M-Exempt | A | Common stock | 200 | 18.09 | 3.6K | 15,683 | D | ↗ |
| 2024-11-08 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 772 | 56.09 | 43.3K | 813 | D | ↗ |
| 2024-11-08 | Ballal Rahul D. | Director | M-Exempt | D | Stock option (right to buy) | 10,000 | 25.99 | 259.9K | 17,947 | D | ↗ |
| 2024-11-07 | Burns James William | Officer | S-Sale | D | Common stock | 13,411 | 52.00 | 697.4K | 24,041 | D | ↗ |
| 2024-11-07 | Ballal Rahul D. | Director | M-Exempt | D | Stock option (right to buy) | 10,000 | 25.99 | 259.9K | 27,947 | D | ↗ |
| 2024-09-26 | Jones Cecilia | Officer | M-Exempt | A | Common stock | 7,473 | 0.00 | — | 22,700 | D | ↗ |
| 2024-08-11 | Smith Cynthia | Director | M-Exempt | D | Restricted stock units | 2,302 | 0.00 | — | 2,302 | — | ↗ |
| 2024-08-11 | Ballal Rahul D. | Director | M-Exempt | D | Restricted stock units | 2,302 | 0.00 | — | 2,302 | — | ↗ |
| 2024-08-08 | Goff Brian | Director / Officer | M-Exempt | A | Common stock | 22,691 | 0.00 | — | 89,883 | — | ↗ |
| 2024-07-01 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 8,375 | 0.00 | — | 47,441 | — | ↗ |
| 2024-06-20 | Smith Cynthia | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | Schenkein David P | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | Scadden David | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | Owen Catherine E. | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | Ho Maykin | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | Foster-Cheek Kaye I | Director | A-Award | A | Stock options (right to buy) | 11,774 | 42.45 | 499.8K | 11,774 | — | ↗ |
| 2024-06-20 | FOUSE JACQUALYN A | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | CAPELLO JEFFREY D | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-20 | Ballal Rahul D. | Director | A-Award | A | Restricted stock units | 2,120 | 0.00 | — | 2,120 | — | ↗ |
| 2024-06-13 | Smith Cynthia | Director | M-Exempt | A | Common stock | 3,388 | 0.00 | — | 5,690 | — | ↗ |
| 2024-06-13 | Schenkein David P | Director | M-Exempt | D | Restricted stock units | 3,388 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | Scadden David | Director | M-Exempt | D | Restricted stock units | 3,388 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | Owen Catherine E. | Director | M-Exempt | D | Restricted stock units | 1,976 | 0.00 | — | 3,953 | — | ↗ |
| 2024-06-13 | Ho Maykin | Director | M-Exempt | A | Common stock | 3,388 | 0.00 | — | 14,912 | — | ↗ |
| 2024-06-13 | Foster-Cheek Kaye I | Director | M-Exempt | D | Restricted stock units | 3,388 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | FOUSE JACQUALYN A | Director | M-Exempt | D | Restricted stock units | 3,388 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | CAPELLO JEFFREY D | Director | M-Exempt | D | Restricted stock units | 1,976 | 0.00 | — | 3,953 | — | ↗ |
| 2024-06-13 | Ballal Rahul D. | Director | M-Exempt | D | Restricted stock units | 3,388 | 0.00 | — | 0 | — | ↗ |
| 2024-06-05 | Goff Brian | Director / Officer | M-Exempt | D | Performance share units | 25,527 | 0.00 | — | 76,583 | — | ↗ |
| 2024-06-03 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 1,362 | 44.39 | 60.5K | 1,524 | — | ↗ |
| 2024-04-10 | FOUSE JACQUALYN A | Director | S-Sale | D | Common stock | 7,791 | 27.55 | 214.6K | 137,396 | — | ↗ |
| 2024-04-08 | FOUSE JACQUALYN A | Director | M-Exempt | A | Common stock | 15,934 | 0.00 | — | 145,187 | — | ↗ |
| 2024-03-07 | Foster-Cheek Kaye I | Director | S-Sale | D | Common stock | 1,285 | 31.62 | 40.6K | 5,524 | — | ↗ |
| 2024-03-06 | Foster-Cheek Kaye I | Director | S-Sale | D | Common stock | 4,415 | 31.99 | 141.2K | 6,809 | — | ↗ |
| 2024-03-05 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 919 | 32.57 | 29.9K | 4,799 | — | ↗ |
| 2024-03-05 | Jones Cecilia | Officer | S-Sale | D | Common stock | 672 | 32.57 | 21.9K | 14,840 | — | ↗ |
| 2024-03-05 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 4,156 | 32.57 | 135.4K | 53,780 | — | ↗ |
| 2024-03-05 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 1,293 | 32.57 | 42.1K | 36,415 | — | ↗ |
| 2024-03-05 | Foster-Cheek Kaye I | Director | S-Sale | D | Common stock | 300 | 32.21 | 9.7K | 11,224 | — | ↗ |
| 2024-03-05 | Burns James William | Officer | S-Sale | D | Common stock | 1,349 | 32.57 | 43.9K | 37,169 | — | ↗ |
| 2024-03-01 | Washburn Theodore James Jr. | Officer | M-Exempt | D | Restricted stock units | 777 | 0.00 | — | 777 | — | ↗ |
| 2024-03-01 | Milanova Tsveta | Officer | A-Award | A | Stock options (right to buy) | 60,000 | 32.27 | 1.94M | 60,000 | — | ↗ |
| 2024-03-01 | Jones Cecilia | Officer | A-Award | A | Stock options (right to buy) | 60,000 | 32.27 | 1.94M | 60,000 | — | ↗ |
| 2024-03-01 | Goff Brian | Director / Officer | A-Award | A | Stock options (right to buy) | 195,500 | 32.27 | 6.31M | 195,500 | — | ↗ |
| 2024-03-01 | Gheuens Sarah | Officer | A-Award | A | Stock options (right to buy) | 60,000 | 32.27 | 1.94M | 60,000 | — | ↗ |
| 2024-03-01 | Burns James William | Officer | M-Exempt | D | Restricted stock units | 4,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-02-27 | Schenkein David P | Director | S-Sale | D | Common stock | 57,471 | 34.89 | 2.01M | 122,854 | — | ↗ |
| 2024-02-26 | Schenkein David P | Director | M-Exempt | A | Common stock | 20,411 | 31.64 | 645.8K | 143,265 | — | ↗ |
| 2024-02-23 | Schenkein David P | Director | M-Exempt | A | Common stock | 47,731 | 31.64 | 1.51M | 170,585 | — | ↗ |
| 2024-02-20 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 504 | 26.63 | 13.4K | 2,741 | — | ↗ |
| 2024-02-14 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 273 | 25.14 | 6.9K | 3,245 | — | ↗ |
| 2024-02-14 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 642 | 25.14 | 16.1K | 33,431 | — | ↗ |
| 2024-02-14 | Burns James William | Officer | S-Sale | D | Common stock | 545 | 25.14 | 13.7K | 31,666 | — | ↗ |
| 2024-02-12 | Washburn Theodore James Jr. | Officer | M-Exempt | A | Common stock | 777 | 0.00 | — | 3,518 | — | ↗ |
| 2024-02-12 | Gheuens Sarah | Officer | M-Exempt | D | Restricted stock units | 2,162 | 0.00 | — | 0 | — | ↗ |
| 2024-02-12 | Burns James William | Officer | M-Exempt | A | Common stock | 1,833 | 0.00 | — | 32,211 | — | ↗ |
| 2024-01-24 | Milanova Tsveta | Officer | S-Sale | D | Common stock | 1,618 | 21.64 | 35.0K | 13,234 | — | ↗ |
| 2024-01-24 | Jones Cecilia | Officer | S-Sale | D | Common stock | 1,886 | 21.64 | 40.8K | 13,069 | — | ↗ |
| 2024-01-24 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 7,635 | 21.64 | 165.2K | 49,436 | — | ↗ |
| 2024-01-24 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 1,708 | 21.64 | 37.0K | 31,911 | — | ↗ |
| 2024-01-24 | FOUSE JACQUALYN A | Director | S-Sale | D | Common stock | 10,722 | 21.64 | 232.0K | 129,253 | — | ↗ |
| 2024-01-24 | Burns James William | Officer | S-Sale | D | Common stock | 1,708 | 21.64 | 37.0K | 30,378 | — | ↗ |
| 2024-01-20 | Milanova Tsveta | Officer | M-Exempt | D | Performance share units | 5,448 | 0.00 | — | 0 | — | ↗ |
| 2024-01-20 | Jones Cecilia | Officer | M-Exempt | D | Performance share units | 5,380 | 0.00 | — | 0 | — | ↗ |
| 2024-01-20 | Goff Brian | Director / Officer | M-Exempt | D | Performance share units | 17,018 | 0.00 | — | 102,110 | — | ↗ |
| 2024-01-20 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 5,750 | 0.00 | — | 33,619 | — | ↗ |
| 2024-01-20 | FOUSE JACQUALYN A | Director | M-Exempt | D | Performance share units | 23,900 | 0.00 | — | 0 | — | ↗ |
| 2024-01-20 | Burns James William | Officer | M-Exempt | A | Common stock | 5,750 | 0.00 | — | 32,086 | — | ↗ |
| 2024-01-09 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 12,066 | 22.99 | 277.4K | 40,053 | — | ↗ |
| 2024-01-09 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 1,789 | 22.99 | 41.1K | 27,869 | — | ↗ |
| 2024-01-09 | FOUSE JACQUALYN A | Director | S-Sale | D | Common stock | 8,391 | 22.99 | 192.9K | 116,075 | — | ↗ |
| 2024-01-09 | Burns James William | Officer | S-Sale | D | Common stock | 1,163 | 22.99 | 26.7K | 26,336 | — | ↗ |
| 2024-01-05 | Milanova Tsveta | Officer | S-Sale | D | Common stock | 2,902 | 22.32 | 64.8K | 9,404 | — | ↗ |
| 2024-01-05 | Goff Brian | Director / Officer | M-Exempt | A | Common stock | 25,527 | 0.00 | — | 52,119 | — | ↗ |
| 2024-01-05 | Gheuens Sarah | Officer | M-Exempt | D | Performance share units | 5,000 | 0.00 | — | 0 | — | ↗ |
| 2024-01-05 | FOUSE JACQUALYN A | Director | M-Exempt | A | Common stock | 17,500 | 0.00 | — | 124,466 | — | ↗ |
| 2024-01-05 | Burns James William | Officer | M-Exempt | D | Performance share units | 3,250 | 0.00 | — | 0 | — | ↗ |
| 2024-01-03 | Milanova Tsveta | Officer | M-Exempt | D | Restricted stock units | 8,475 | 0.00 | — | 16,951 | — | ↗ |
| 2023-09-28 | Jones Cecilia | Officer | S-Sale | D | Common stock | 2,179 | 24.79 | 54.0K | 9,575 | — | ↗ |
| 2023-09-26 | Jones Cecilia | Officer | M-Exempt | D | Restricted stock units | 7,472 | 0.00 | — | 14,945 | — | ↗ |
| 2023-08-17 | Burns James William | Officer | S-Sale | D | Common stock | 6,395 | 26.28 | 168.1K | 23,890 | — | ↗ |
| 2023-08-11 | Smith Cynthia | Director | M-Exempt | D | Restricted stock units | 2,302 | 0.00 | — | 4,604 | — | ↗ |
| 2023-08-11 | Ballal Rahul D. | Director | M-Exempt | D | Restricted stock units | 2,302 | 0.00 | — | 4,604 | — | ↗ |
| 2023-08-09 | Foster-Cheek Kaye I | Director | M-Exempt | A | Common stock | 25,000 | 18.09 | 452.3K | 36,524 | — | ↗ |
| 2023-08-08 | Goff Brian | Director / Officer | M-Exempt | D | Restricted stock units | 22,691 | 0.00 | — | 45,382 | — | ↗ |
| 2023-08-07 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 2,918 | 25.39 | 74.1K | 2,741 | — | ↗ |
| 2023-08-01 | Washburn Theodore James Jr. | Officer | S-Sale | D | Common stock | 1,232 | 26.26 | 32.4K | 5,659 | — | ↗ |
| 2023-07-01 | Gheuens Sarah | Officer | A-Award | A | Restricted stock units | 25,124 | 0.00 | — | 25,124 | — | ↗ |
| 2023-06-30 | Milanova Tsveta | Officer | S-Sale | D | Common stock | 1,618 | 28.36 | 45.9K | 3,831 | — | ↗ |
| 2023-06-30 | Jones Cecilia | Officer | S-Sale | D | Common stock | 1,597 | 28.36 | 45.3K | 3,783 | — | ↗ |
| 2023-06-30 | Goff Brian | Director / Officer | S-Sale | D | Common stock | 11,449 | 28.36 | 324.7K | 14,079 | — | ↗ |
| 2023-06-30 | Gheuens Sarah | Officer | S-Sale | D | Common stock | 1,707 | 28.36 | 48.4K | 24,159 | — | ↗ |
| 2023-06-30 | FOUSE JACQUALYN A | Director | S-Sale | D | Common stock | 10,718 | 28.36 | 304.0K | 106,966 | — | ↗ |
| 2023-06-30 | Burns James William | Officer | S-Sale | D | Common stock | 1,707 | 28.36 | 48.4K | 30,285 | — | ↗ |
| 2023-06-28 | Milanova Tsveta | Officer | M-Exempt | A | Common stock | 5,449 | 0.00 | — | 5,449 | — | ↗ |
| 2023-06-28 | Jones Cecilia | Officer | M-Exempt | A | Common stock | 5,380 | 0.00 | — | 5,380 | — | ↗ |
| 2023-06-28 | Goff Brian | Director / Officer | M-Exempt | A | Common stock | 25,528 | 0.00 | — | 25,528 | — | ↗ |
| 2023-06-28 | Gheuens Sarah | Officer | M-Exempt | A | Common stock | 5,750 | 0.00 | — | 25,866 | — | ↗ |
| 2023-06-28 | FOUSE JACQUALYN A | Director | M-Exempt | D | Performance share units | 23,900 | 0.00 | — | 23,900 | — | ↗ |
| 2023-06-28 | Burns James William | Officer | M-Exempt | D | Performance share units | 5,750 | 0.00 | — | 5,750 | — | ↗ |
| 2023-06-21 | Schenkein David P | Director | M-Exempt | D | Restricted stock unit | 4,975 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | Scadden David | Director | M-Exempt | D | Restricted stock unit | 4,975 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | Ho Maykin | Director | M-Exempt | D | Restricted stock unit | 4,975 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | Foster-Cheek Kaye I | Director | M-Exempt | D | Restricted stock unit | 4,975 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Smith Cynthia | Director | A-Award | A | Restricted stock units | 3,388 | 0.00 | — | 3,388 | — | ↗ |
| 2023-06-13 | Schenkein David P | Director | A-Award | A | Restricted stock units | 3,388 | 0.00 | — | 3,388 | — | ↗ |
| 2023-06-13 | Scadden David | Director | A-Award | A | Stock options (right to buy) | 18,958 | 26.56 | 503.5K | 18,958 | — | ↗ |
| 2023-06-13 | Owen Catherine E. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Ho Maykin | Director | A-Award | A | Restricted stock units | 3,388 | 0.00 | — | 3,388 | — | ↗ |
| 2023-06-13 | Foster-Cheek Kaye I | Director | A-Award | A | Restricted stock units | 3,388 | 0.00 | — | 3,388 | — | ↗ |
| 2023-06-13 | FOUSE JACQUALYN A | Director | A-Award | A | Stock options (right to buy) | 18,958 | 26.56 | 503.5K | 18,958 | — | ↗ |
| 2023-06-13 | CAPELLO JEFFREY D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Ballal Rahul D. | Director | A-Award | A | Stock options (right to buy) | 18,958 | 26.56 | 503.5K | 18,958 | — | ↗ |
| 2023-04-12 | FOUSE JACQUALYN A | Director | F-InKind | D | Common stock | 4,731 | 21.35 | 101.0K | 93,784 | — | ↗ |
| 2023-04-08 | FOUSE JACQUALYN A | Director | M-Exempt | A | Common stock | 15,933 | 0.00 | — | 98,515 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.7K
Shares Outstanding
59.47M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brian Goff Chief Executive Officer | 846.9K | — | 1.29M | 2.63M | 592.8K | 11.8K | 5.37M | 72.97% | ↗ |
| 2 | 2025 | Krishnan Viswanadhan, Pharm.D Chief Corporate Development & Strategy Officer | 433.1K | 250.0K | 825.0K | 1.05M | 236.3K | 12.1K | 2.81M | 66.79% | ↗ |
| 3 | 2025 | Cecilia Jones Chief Financial Officer | 535.1K | — | 924.4K | 802.0K | 240.8K | 16.0K | 2.52M | 68.56% | ↗ |
| 4 | 2025 | James Burns Chief Legal Officer | 527.3K | — | 786.9K | 802.0K | 237.3K | 16.0K | 2.37M | 67.06% | ↗ |
| 5 | 2025 | Sarah Gheuens, M.D., Ph.D. Chief Medical Officer, Head of Research & Development | 601.1K | — | 397.4K | 802.0K | 270.5K | 15.7K | 2.09M | 57.48% | ↗ |
| 6 | 2024 | Brian Goff Chief Executive Officer | 822.2K | — | 1.74M | 3.48M | 719.4K | 11.7K | 6.78M | 77.08% | ↗ |
| 7 | 2024 | Sarah Gheuens, M.D., Ph.D. Chief Medical Officer, Head of Research & Development | 583.5K | — | 548.6K | 1.07M | 328.2K | 15.9K | 2.54M | 63.54% | ↗ |
| 8 | 2024 | Tsveta Milanova Chief Commercial Officer | 525.3K | — | 548.6K | 1.07M | 295.5K | 15.9K | 2.45M | 65.90% | ↗ |
| 9 | 2024 | James Burns Chief Legal Officer | 511.9K | — | 548.6K | 1.07M | 288.0K | 15.9K | 2.43M | 66.47% | ↗ |
| 10 | 2024 | Cecilia Jones Chief Financial Officer | 503.9K | — | 548.6K | 1.07M | 283.4K | 15.3K | 2.42M | 66.83% | ↗ |
| 11 | 2023 | Tsveta Milanova Chief Commercial Officer | 507.9K | 150.0K | 700.0K | 2.09M | 266.2K | 15.0K | 3.73M | 74.85% | ↗ |
| 12 | 2023 | Brian Goff Chief Executive Officer | 798.3K | — | 637.8K | 1.32M | 648.2K | 12.5K | 3.42M | 57.30% | ↗ |
| 13 | 2023 | Sarah Gheuens, M.D., Ph.D. Chief Medical Officer, Head of Research & Development | 566.5K | — | 1.01M | 614.5K | 667.0K | 14.1K | 2.87M | 56.53% | ↗ |
| 14 | 2023 | James Burns Chief Legal Officer | 497.0K | — | 300.1K | 614.5K | 507.8K | 15.1K | 1.93M | 47.28% | ↗ |
| 15 | 2023 | Cecilia Jones Chief Financial Officer | 484.5K | — | 150.1K | 307.2K | 252.9K | 14.1K | 1.21M | 37.83% | ↗ |
| 16 | 2022 | Brian Goff Chief Executive Officer | 308.2K | 250.0K | 2.00M | 8.98M | 195.3K | 9.8K | 11.74M | 93.50% | ↗ |
| 17 | 2022 | Jacqualyn A. Fouse, Ph.D. Former Chief Executive Officer | 466.8K | — | 1.41M | 2.73M | 293.0K | 10.3K | 4.91M | 84.32% | ↗ |
| 18 | 2022 | Cecilia Jones Chief Financial Officer | 127.7K | 175.0K | 625.0K | 1.88M | 96.2K | 4.4K | 2.91M | 86.14% | ↗ |
| 19 | 2022 | Richa Poddar Former Chief Commercial Officer | 450.0K | — | 370.3K | 707.4K | — | 398.8K | 1.93M | 55.94% | ↗ |
| 20 | 2022 | Bruce Car, Ph.D. Former Chief Scientific Officer | 309.4K | — | 370.3K | 707.4K | — | 465.3K | 1.85M | 58.18% | ↗ |
| 21 | 2022 | Sarah Gheuens, M.D., Ph.D. Chief Medical Officer, Head of Research & Development | 532.5K | — | 370.3K | 707.4K | 222.8K | 14.0K | 1.85M | 58.35% | ↗ |
| 22 | 2022 | James Burns Chief Legal Officer | 460.0K | — | 370.3K | 707.4K | 186.3K | 14.0K | 1.74M | 62.01% | ↗ |
| 23 | 2022 | Jonathan Biller Former Chief Financial Officer, Head of Corporate Affairs | 388.9K | — | 370.3K | 707.4K | — | 11.5K | 1.48M | 72.91% | ↗ |
| 24 | 2021 | Jacqualyn A. Fouse, Ph.D. Former Chief Executive Officer | 760.0K | — | — | 5.20M | 543.4K | 13.5K | 6.52M | 79.80% | ↗ |
| 25 | 2021 | Jacqualyn A. Fouse, Ph.D. Chief Executive Officer | 760.0K | — | — | 5.20M | 543.4K | 13.5K | 6.52M | 79.80% | ↗ |
| 26 | 2021 | Jonathan Biller Chief Financial Officer, Head of Corporate Affairs | 530.1K | — | 623.5K | 1.40M | 262.4K | 11.6K | 2.83M | 71.60% | ↗ |
| 27 | 2021 | Jonathan Biller Former Chief Financial Officer, Head of Corporate Affairs | 530.1K | — | 623.5K | 1.40M | 262.4K | 11.6K | 2.83M | 71.60% | ↗ |
| 28 | 2021 | Bruce Car, Ph.D. Former Chief Scientific Officer | 515.0K | — | 623.5K | 1.40M | 254.9K | 6.2K | 2.80M | 72.32% | ↗ |
| 29 | 2021 | Bruce Car, Ph.D. Chief Scientific Officer | 515.0K | — | 623.5K | 1.40M | 254.9K | 6.2K | 2.80M | 72.32% | ↗ |
| 30 | 2021 | Christopher Bowden, M.D. Former Chief Medical Officer | 475.2K | — | 623.5K | 1.40M | 262.6K | 9.2K | 2.77M | 73.08% | ↗ |
| 31 | 2021 | Darrin Miles Former Chief Commercial Officer | 444.2K | — | 623.5K | 1.40M | — | 1.7K | 2.47M | 81.97% | ↗ |
| 32 | 2021 | Sarah Gheuens, M.D., Ph.D. Chief Medical Officer, Head of Research & Development | 437.6K | — | 367.6K | 103.5K | 247.5K | 13.3K | 1.17M | 40.29% | ↗ |
| 33 | 2021 | Sarah Gheuens, M.D., Ph.D. Chief Medical Officer | 437.6K | — | 367.6K | 103.5K | 247.5K | 13.3K | 1.17M | 40.29% | ↗ |
| 34 | 2021 | Richa Poddar Chief Commercial Officer | 387.9K | — | 351.6K | 99.0K | 222.8K | 13.4K | 1.07M | 41.93% | ↗ |
| 35 | 2021 | Richa Poddar Former Chief Commercial Officer | 387.9K | — | 351.6K | 99.0K | 222.8K | 13.4K | 1.07M | 41.93% | ↗ |
| 36 | 2020 | Jacqualyn A. Fouse, Ph.D. Former Chief Executive Officer | 746.8K | — | 1.75M | 4.59M | 509.7K | 10.6K | 7.61M | 83.36% | ↗ |
| 37 | 2020 | Jacqualyn A. Fouse, Ph.D. Chief Executive Officer | 746.8K | — | 1.75M | 4.59M | 509.7K | 10.6K | 7.61M | 83.36% | ↗ |
| 38 | 2020 | Bruce Car, Ph.D. Chief Scientific Officer | 494.3K | — | 833.3K | 1.50M | 236.3K | 164.2K | 3.23M | 72.28% | ↗ |
| 39 | 2020 | Bruce Car, Ph.D. Former Chief Scientific Officer | 494.3K | — | 833.3K | 1.50M | 236.3K | 164.2K | 3.23M | 72.28% | ↗ |
| 40 | 2020 | Christopher Bowden, M.D. Chief Medical Officer | 515.0K | — | 618.1K | 1.51M | 243.3K | 9.2K | 2.89M | 73.48% | ↗ |
| 41 | 2020 | Christopher Bowden, M.D. Former Chief Medical Officer | 515.0K | — | 618.1K | 1.51M | 243.3K | 9.2K | 2.89M | 73.48% | ↗ |
| 42 | 2020 | Andrew Hirsch Former Chief Financial Officer | 361.2K | — | 618.1K | 1.51M | — | 397.9K | 2.89M | 73.70% | ↗ |
| 43 | 2020 | Jonathan Biller Former Chief Financial Officer, Head of Corporate Affairs | 500.0K | — | — | — | 258.8K | 10.6K | 769.3K | 0.00% | ↗ |
| 44 | 2020 | Jonathan Biller Chief Financial Officer, Head of Corporate Affairs | 500.0K | — | — | — | 258.8K | 10.6K | 769.3K | 0.00% | ↗ |
| 45 | 2020 | Jonathan Biller Chief Financial Officer, Head of Legal and Corporate Affairs | 500.0K | — | — | — | 258.8K | 10.6K | 769.3K | 0.00% | ↗ |
| 46 | 2019 | Jacqualyn A. Fouse, Ph.D. Chief Executive Officer | 664.6K | — | 2.54M | 12.88M | 424.1K | 105.2K | 16.61M | 92.81% | ↗ |
| 47 | 2019 | Andrew Hirsch Former Chief Financial Officer | 500.5K | — | 1.92M | 1.61M | 202.7K | 12.5K | 4.25M | 83.16% | ↗ |
| 48 | 2019 | Andrew Hirsch Chief Financial Officer | 500.5K | — | 1.92M | 1.61M | 202.7K | 12.5K | 4.25M | 83.16% | ↗ |
| 49 | 2019 | Christopher Bowden, M.D. Former Chief Medical Officer | 490.5K | — | 915.6K | 1.61M | 198.7K | 12.4K | 3.23M | 78.26% | ↗ |
| 50 | 2019 | Christopher Bowden, M.D. Chief Medical Officer | 490.5K | — | 915.6K | 1.61M | 198.7K | 12.4K | 3.23M | 78.26% | ↗ |
| 51 | 2019 | Scott Biller, Ph.D. Chief Scientific Officer | 480.0K | — | 908.6K | 1.61M | 194.9K | 12.6K | 3.21M | 78.55% | ↗ |
| 52 | 2019 | Jonathan Biller Chief Financial Officer, Head of Corporate Affairs | 39.6K | 110.0K | 1.01M | 2.03M | — | 936.00 | 3.18M | 95.27% | ↗ |
| 53 | 2019 | Jonathan Biller Chief Legal Officer | 39.6K | 110.0K | 1.01M | 2.03M | — | 936.00 | 3.18M | 95.27% | ↗ |
| 54 | 2019 | Jonathan Biller Chief Financial Officer, Head of Legal and Corporate Affairs | 39.6K | 110.0K | 1.01M | 2.03M | — | 936.00 | 3.18M | 95.27% | ↗ |
| 55 | 2019 | David P. Schenkein, M.D. Former President and Chief Executive Officer; Executive Chairman | 212.5K | — | 490.0K | 1.84M | 30.5K | 3.3K | 2.58M | 90.44% | ↗ |
| 56 | 2018 | David P. Schenkein, M.D. President and Chief Executive Officer | 625.0K | — | 1.89M | 5.16M | 507.8K | 12.4K | 8.20M | 86.03% | ↗ |
| 57 | 2018 | David P. Schenkein, M.D. Former President and Chief Executive Officer; Executive Chairman | 625.0K | — | 1.89M | 5.16M | 507.8K | 12.4K | 8.20M | 86.03% | ↗ |
| 58 | 2018 | Andrew Hirsch Former Chief Financial Officer | 471.3K | — | 641.0K | 1.75M | 265.1K | 12.9K | 3.14M | 76.11% | ↗ |
| 59 | 2018 | Andrew Hirsch Chief Financial Officer and Head of Corporate Development | 471.3K | — | 641.0K | 1.75M | 265.1K | 12.9K | 3.14M | 76.11% | ↗ |
| 60 | 2018 | Andrew Hirsch Chief Financial Officer | 471.3K | — | 641.0K | 1.75M | 265.1K | 12.9K | 3.14M | 76.11% | ↗ |
| 61 | 2018 | Christopher Bowden, M.D. Chief Medical Officer | 467.1K | — | 641.0K | 1.75M | 262.8K | 11.3K | 3.13M | 76.31% | ↗ |
| 62 | 2018 | Scott Biller, Ph.D. Chief Scientific Officer | 446.6K | — | 641.0K | 1.75M | 251.2K | 12.7K | 3.10M | 77.07% | ↗ |
| 63 | 2018 | Steve Hoerter Chief Commercial Officer | 444.5K | — | 641.0K | 1.75M | 250.1K | 14.6K | 3.10M | 77.10% | ↗ |
| 64 | 2017 | David P. Schenkein, M.D. President and Chief Executive Officer | 585.0K | — | — | 4.92M | 456.3K | 9.5K | 5.97M | 82.40% | ↗ |
| 65 | 2017 | David P. Schenkein, M.D. Former President and Chief Executive Officer; Executive Chairman | 585.0K | — | — | 4.92M | 456.3K | 9.5K | 5.97M | 82.40% | ↗ |
| 66 | 2017 | Christopher Bowden, M.D. Chief Medical Officer | 449.2K | — | — | 1.64M | 233.6K | 8.7K | 2.33M | 70.33% | ↗ |
| 67 | 2017 | Andrew Hirsch Chief Financial Officer | 453.2K | — | — | 1.64M | 217.5K | 10.0K | 2.32M | 70.66% | ↗ |
| 68 | 2017 | Andrew Hirsch Chief Financial Officer and Head of Corporate Development | 453.2K | — | — | 1.64M | 217.5K | 10.0K | 2.32M | 70.66% | ↗ |
| 69 | 2017 | Scott Biller, Ph.D. Chief Scientific Officer | 429.4K | — | — | 1.64M | 223.3K | 9.8K | 2.30M | 71.22% | ↗ |
| 70 | 2017 | Steve Hoerter Chief Commercial Officer | 427.5K | — | — | 1.64M | 205.2K | 9.4K | 2.28M | 71.86% | ↗ |
| 71 | 2016 | Andrew Hirsch Chief Financial Officer and Head of Corporate Development | 126.7K | — | 747.5K | 4.19M | 176.0K | 698.00 | 5.24M | 94.21% | ↗ |
| 72 | 2016 | Andrew Hirsch Chief Financial Officer | 126.7K | — | 747.5K | 4.19M | 176.0K | 698.00 | 5.24M | 94.21% | ↗ |
| 73 | 2016 | Steve Hoerter Chief Commercial Officer | 363.1K | 375.0K | 596.4K | 2.53M | 166.0K | 9.5K | 4.04M | 77.37% | ↗ |
| 74 | 2016 | David P. Schenkein, M.D. President and Chief Executive Officer | 568.0K | — | — | 2.58M | 340.8K | 9.9K | 3.50M | 73.76% | ↗ |
| 75 | 2016 | Christopher Bowden, M.D. Chief Medical Officer | 436.1K | — | — | 1.15M | 174.4K | 9.1K | 1.77M | 64.91% | ↗ |
| 76 | 2016 | Scott Biller, Ph.D. Chief Scientific Officer | 416.9K | — | — | 1.15M | 166.8K | 10.2K | 1.74M | 65.87% | ↗ |
| 77 | 2016 | Glenn Goddard Former Sr. Vice President, Finance | 271.6K | — | — | 515.2K | — | 155.3K | 942.1K | 54.69% | ↗ |
| 78 | 2015 | David P. Schenkein, M.D. President and Chief Executive Officer | 517.5K | — | — | 9.29M | 295.0K | 10.1K | 10.11M | 91.87% | ↗ |
| 79 | 2015 | Scott Biller, Ph.D. Chief Scientific Officer | 400.9K | — | — | 4.65M | 152.3K | 10.0K | 5.21M | 89.19% | ↗ |
| 80 | 2015 | J. Duncan Higgons Former Chief Operating Officer | 388.1K | — | — | 4.65M | 147.5K | 10.0K | 5.19M | 89.49% | ↗ |
| 81 | 2015 | Glenn Goddard Sr. Vice President, Finance | 318.3K | — | — | 2.09M | 105.8K | 9.9K | 2.53M | 82.83% | ↗ |
| 82 | 2015 | Glenn Goddard Former Sr. Vice President, Finance | 318.3K | — | — | 2.09M | 105.8K | 9.9K | 2.53M | 82.83% | ↗ |
| 83 | 2015 | Christopher Bowden, M.D. Chief Medical Officer | 403.8K | 150.0K | 403.7K | 1.16M | 153.4K | 10.0K | 2.29M | 68.61% | ↗ |
| 84 | 2014 | David P. Schenkein, M.D. President and Chief Executive Officer | 500.0K | — | — | 3.49M | 371.3K | 2.0K | 4.36M | 79.97% | ↗ |
| 85 | 2014 | David P. Schenkein, M.D. Chief Executive Officer | 500.0K | — | — | 3.49M | 371.3K | 2.0K | 4.36M | 79.97% | ↗ |
| 86 | 2014 | Christopher Bowden, M.D. Chief Medical Officer | 251.4K | 120.0K | — | 2.92M | 135.6K | 1.1K | 3.43M | 85.17% | ↗ |
| 87 | 2014 | Christopher Bowden, M.D. Chief Medical Officer | 251.4K | 120.0K | — | 2.92M | 135.6K | 1.1K | 3.43M | 85.17% | ↗ |
| 88 | 2014 | Scott Biller, Ph.D. Chief Scientific Officer | 387.3K | — | — | 1.74M | 209.1K | 2.3K | 2.34M | 74.44% | ↗ |
| 89 | 2014 | Scott Biller, Ph.D. Chief Scientific Officer | 387.3K | — | — | 1.74M | 209.1K | 2.3K | 2.34M | 74.44% | ↗ |
| 90 | 2014 | J. Duncan Higgons Former Chief Operating Officer | 375.0K | — | — | 1.74M | 202.5K | 2.0K | 2.32M | 75.06% | ↗ |
| 91 | 2014 | J. Duncan Higgons Chief Operating Officer | 375.0K | — | — | 1.74M | 202.5K | 2.0K | 2.32M | 75.06% | ↗ |
| 92 | 2014 | Glenn Goddard Sr. Vice President, Finance | 309.0K | — | — | 1.37M | 131.4K | 1.9K | 1.82M | 75.65% | ↗ |
| 93 | 2014 | Glenn Goddard Former Sr. Vice President, Finance | 309.0K | — | 502.4K | 871.5K | 131.4K | 1.9K | 1.82M | 75.65% | ↗ |
| 94 | 2014 | Glenn Goddard Sr. Vice President, Finance | 309.0K | — | 502.4K | 871.5K | 131.4K | 1.9K | 1.82M | 75.65% | ↗ |
| 95 | 2013 | David P. Schenkein, M.D. Chief Executive Officer | 425.0K | — | — | 957.1K | 204.0K | 3.0K | 1.59M | 60.23% | ↗ |
| 96 | 2013 | David P. Schenkein, M.D. President and Chief Executive Officer | 425.0K | — | — | 957.1K | 204.0K | 3.0K | 1.59M | 60.23% | ↗ |
| 97 | 2013 | Glenn Goddard Sr. Vice President, Finance | 269.1K | — | — | 1.08M | 117.0K | 2.3K | 1.47M | 73.49% | ↗ |
| 98 | 2013 | Glenn Goddard Sr. Vice President, Finance | 269.1K | — | — | 1.08M | 117.0K | 2.3K | 1.47M | 73.49% | ↗ |
| 99 | 2013 | Scott Biller, Ph.D. Chief Scientific Officer | 376.0K | — | — | 478.5K | 157.9K | 3.1K | 1.02M | 47.12% | ↗ |
| 100 | 2013 | Scott Biller, Ph.D. Chief Scientific Officer | 376.0K | — | — | 478.5K | 157.9K | 3.1K | 1.02M | 47.12% | ↗ |
| 101 | 2013 | J. Duncan Higgons Chief Operating Officer | 350.0K | — | — | 478.5K | 147.0K | 2.7K | 978.2K | 48.92% | ↗ |
| 102 | 2013 | J. Duncan Higgons Former Chief Operating Officer | 350.0K | — | — | 478.5K | 147.0K | 2.7K | 978.2K | 48.92% | ↗ |
| 103 | 2013 | Christopher Bowden, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2012 | David P. Schenkein, M.D. Chief Executive Officer | 425.0K | — | — | — | 136.0K | 2.8K | 698.3K | 0.00% | ↗ |
| 105 | 2012 | Scott Biller, Ph.D. Chief Scientific Officer | 376.0K | — | — | — | 105.3K | 3.1K | 602.0K | 0.00% | ↗ |
| 106 | 2012 | J. Duncan Higgons Chief Operating Officer | 350.0K | — | — | — | 98.0K | 2.7K | 568.4K | 0.00% | ↗ |
| 107 | 2012 | Glenn Goddard Sr. Vice President, Finance | 253.7K | — | — | — | 30.4K | 2.3K | 340.2K | 0.00% | ↗ |
| 108 | 2012 | Christopher Bowden, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 109 | 2011 | David P. Schenkein, M.D. Chief Executive Officer | 425.0K | — | — | — | 170.0K | 2.8K | 611.2K | 0.00% | ↗ |
| 110 | 2011 | Scott Biller, Ph.D. Chief Scientific Officer | 376.0K | — | — | — | 131.6K | 2.9K | 510.5K | 0.00% | ↗ |
| 111 | 2011 | J. Duncan Higgons Chief Operating Officer | 350.0K | — | — | — | 122.5K | 2.7K | 480.6K | 0.00% | ↗ |
| 112 | 2011 | Glenn Goddard Sr. Vice President, Finance | 244.5K | — | — | — | 40.0K | 2.2K | 292.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Goff | Chief Executive Officer & Director | 1M | male |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 927.6K | — |
| Tsveta Milanova | Chief Commercial Officer | 836.6K | female |
| James William Burns | Corporate Secretary & Chief Legal Officer | 815.7K | male |
| Cecilia Jones | Chief Financial Officer | 802.6K | female |
| Shin-San Su | Co-Founder | 50.0K | — |
| Craig Thompson | Co-Founder | 50.0K | — |
| Lewis Clayton Cantley | Co-Founder | 50.0K | — |
| Tak Wah Mak FRSC | Co-Founder | 50.0K | — |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | — | male |
| Clive Patience | Chief Technical Operations Officer | — | — |
| Steven Vickers | Vice President of Sales | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-03 | 2026-04-08 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-12-11 | 2026-01-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-17 | 2025-05-07 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-01-29 | 2025-02-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-01-24 | 2024-02-15 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
